Today: 19 May 2026
Browse Category

LSE:WOSG 7 December 2025 - 19 January 2026

FTSE 100 Ends Week in the Red as Global Stocks Diverge: World Indices, Outlook and Forecasts (5–7 December 2025)

FTSE 100 Ends Week in the Red as Global Stocks Diverge: World Indices, Outlook and Forecasts (5–7 December 2025)

The FTSE 100 fell 0.5% to 9,667 on Friday, December 5, 2025, its lowest level in over a week, closing out a losing week for UK equities. Energy and bank stocks led declines, with BP down 2.6% and the bank index off 1.2%. Wall Street and Asian markets rose, leaving the UK benchmark trailing global peers ahead of a key US Federal Reserve decision.
7 December 2025
·······
UK Stock Market Outlook: What to Know Before the FTSE 100 Opens on Monday 8 December 2025

UK Stock Market Outlook: What to Know Before the FTSE 100 Opens on Monday 8 December 2025

The FTSE 100 closed Friday at 9,667.01, down 0.5%, as energy and bank stocks fell sharply. The Magnum Ice Cream Company is set to debut in London trading Monday. Investors await a US Federal Reserve rate decision and key UK GDP data later this week. FTSE constituent reshuffles add to market volatility.
7 December 2025
·············

Stock Market Today

  • When Will Island Pharmaceuticals Limited (ASX:ILA) Reach Profitability?
    May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Figma shares test rebound as AI bet delivers

Figma shares test rebound as AI bet delivers

18 May 2026
Figma traded at $23.20 Monday afternoon, valuing the company at $12.1 billion. First-quarter revenue jumped 46% to $333.4 million, and the company raised its 2026 revenue forecast to up to $1.428 billion. Paid customers rose 54% to about 690,000. Figma posted a GAAP net loss of $142.4 million but reported $56.5 million in non-GAAP net income.
Go toTop